Sanoculis

Israel - Kiryat OnoCRO (Contract Research)

Focus: Sanoculis is a medical device company focused on minimally invasive micro sclerostomy technology for glaucoma treatment, based in Israel with a narrow therapeutic focus on ophthalmology.

Ophthalmology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Sanoculis

AI assessmentNot Hiring

No open roles listed right now. Follow Sanoculis to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MINT

This Study is Obtained Under Inclusion/ Exclusion Criteria

N/A

Clinical Trials (1)

NCT05638906Minimally Invasive Nasal Trabeculostomy - Performance and Safety Evaluation Study

N/A

Help build intelligence for Sanoculis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on innovative device technology in a high-need therapeutic area (glaucoma affects ~80M patients globally)
Early-stage company position offers potential equity upside and hands-on involvement in clinical program development
Focused pipeline with 11 active trials suggests execution momentum in a niche but underserved ophthalmology space

Watch Out For

Company shows zero active job openings and limited publicly available financial data, suggesting minimal hiring or transparency into funding status
Founded in 2021 with no disclosed revenue or funding; pre-revenue status creates high financial stability risk and potential runway constraints
All pipeline programs lack phase designation clarity, indicating early-stage development with uncertain timeline to regulatory approval or commercial viability

Generated by Claude from Sanoculis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MIMS

This Study is Conducted Under Inclusion/ Exclusion Criteria

N/A

Clinical Trials (1)

NCT05638321Minimally Invasive Micro Sclerostomy (MIMS®) Inferonasal Procedure - Performance Evaluation Study

N/A

Minimally Invasive Micro Sclerostomy

Primary Open Angle Glaucoma

N/A

Clinical Trials (1)

NCT02355990Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study

N/A

Minimally Invasive Micro Sclerostomy

Glaucoma

N/A

Clinical Trials (1)

NCT04503590Minimally Invasive Micro Sclerostomy: Performance and Safety Evaluation Study

N/A

MIMS

Glaucoma

N/A

Clinical Trials (1)

NCT07051174The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP): The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP)

N/A

Minimally Invasive Micro Sclerostomy Device

Primary Open Angle Glaucoma

N/A

Clinical Trials (1)

NCT06313749Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

N/A

MINT Minimally Invasive Nasal Trabeculostomy

Glaucoma

N/A

Clinical Trials (1)

NCT07081347This Follow-up Extension Study is Aimed to Monitor the Long-term IOP-lowering Performance/Efficacy and Safety of the MINT® Procedure in Open Angle Glaucoma Eyes.

N/A

Minimally Invasive Micro Sclerostomy

Glaucoma

N/A

Clinical Trials (1)

NCT04484155Minimally Invasive Micro Sclerostomy: Safety and Preliminary Performance Study

N/A

Minimally Invasive Micro Sclerostomy

Open Angle Glaucoma

N/A

Clinical Trials (1)

NCT06614218MIMS® Retrospective Chart Review